NCT02392364View on ClinicalTrials.gov

Variable Interval Versus Set Interval Aflibercept for DME

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

November 15, 2018

Study Completion Date

November 15, 2018

Conditions
Cystoid Macular EdemaDiabetic Macular Edema
Interventions
DRUG

Intravitreal Aflibercept Injection

Trial Locations (2)

93039

California Retina Consultants - Bakersfield, Bakersfield

93103

California Retina Consultants - Santa Barbara Office, Santa Barbara

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

California Retina Consultants

OTHER

NCT02392364 - Variable Interval Versus Set Interval Aflibercept for DME | Biotech Hunter | Biotech Hunter